Clinical Trial Update: 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors [Phase 1]

View source ↗

Summary

This update reports progress on a Phase 1 trial of the radiopharmaceutical 177Lu-DOTA-EB-TATE in patients with advanced neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• 177Lu-DOTA-EB-TATE

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Neuroendocrine Tumors | Phase 1 | Status: UNKNOWN